Taishi Onodera

Taishi Onodera

Auto-generated profile, based on publicly available information

Taishi Onodera

Research Center for Drug and Vaccine Development, National Institute of Infectious Diseases, Tokyo, Japan

Research Focus & Metrics

Academic Career Length

30Years (1997-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 October 2021 in Journal of Experimental Medicine
Verified
Journal Article
Open access
PDF file
XLXiuyuan Lu
Xiuyuan Lu
YHYuki Hosono
Yuki Hosono
MNMasamichi Nagae
Masamichi Nagae
SIShigenari Ishizuka
Shigenari Ishizuka
EIEri Ishikawa
Eri Ishikawa
SYSho Yamasaki
Sho Yamasaki
Adaptive immunity is a fundamental component in controlling COVID-19. In this process, follicular helper T (Tfh) cells are a subset of CD4+ T cells that mediate the production of protective antibodies; however, the SARS-CoV-2 epitopes activating Tfh cells are not well characterized. Here, we identified and crystallized TCRs of public circulating Tfh (cTfh) clonotypes that are expanded in patients who have recovered from mild symptoms. These public clonotypes recognized the SARS-CoV-2 spike (S) epitopes conserved across emerging variants. The epitope of the most prevalent cTfh clonotype, S864–882, was presented by multiple HLAs and activated T cells in most healthy donors, suggesting that this S region is a universal T cell epitope useful for booster antigen. SARS-CoV-2–specific public cTfh clonotypes also cross-reacted with specific commensal bacteria. In this study, we identified conserved SARS-CoV-2 S epitopes that activate public cTfh clonotypes associated with mild symptoms.

29 January 2022 in Biochemical and Biophysical Research Communications
Verified
Journal Article
Closed access
MMMana Murae
Mana Murae
YSYoshimi Shimizu
Yoshimi Shimizu
YYYuichiro Yamamoto
Yuichiro Yamamoto
AKAsuka Kobayashi
Asuka Kobayashi
MHMasumi Houri
Masumi Houri
KNKohji Noguchi
Kohji Noguchi

8 October 2021 in Journal of Experimental Medicine
Verified
Journal Article
Open access
PDF file
RSRyo Shinnakasu
Ryo Shinnakasu
SSShuhei Sakakibara
Shuhei Sakakibara
HYHiromi Yamamoto
Hiromi Yamamoto
PWPo-Hung Wang
Po-Hung Wang
SMSaya Moriyama
Saya Moriyama
TKTomohiro Kurosaki
Tomohiro Kurosaki
Broadly protective vaccines against SARS-related coronaviruses that may cause future outbreaks are urgently needed. The SARS-CoV-2 spike receptor-binding domain (RBD) comprises two regions, the core-RBD and the receptor-binding motif (RBM); the former is structurally conserved between SARS-CoV-2 and SARS-CoV. Here, in order to elicit humoral responses to the more conserved core-RBD, we introduced N-linked glycans onto RBM surfaces of the SARS-CoV-2 RBD and used them as immunogens in a mouse model. We found that glycan addition elicited higher proportions of the core-RBD–specific germinal center (GC) B cells and antibody responses, thereby manifesting significant neutralizing activity for SARS-CoV, SARS-CoV-2, and the bat WIV1-CoV. These results have implications for the design of SARS-like virus vaccines.

21 August 2024 in Science Translational Medicine
Verified
Journal Article
Closed access
RKRyutaro Kotaki
Ryutaro Kotaki
SMSaya Moriyama
Saya Moriyama
SOShintaro Oishi
Shintaro Oishi
TOTaishi Onodera
Taishi Onodera
YAYu Adachi
Yu Adachi
YTYoshimasa Takahashi
Yoshimasa Takahashi
Immunological imprinting by ancestral SARS-CoV-2 strains is thought to impede the robust induction of Omicron-specific humoral responses by Omicron-based booster vaccines. Here, we analyzed the specificity and neutralization activity of memory B (B mem ) cells after repeated BA.5 exposure in individuals previously imprinted by ancestral strain–based mRNA vaccines. After a second BA.5 exposure, B mem cells with BA.5 spike protein–skewed reactivity were promptly elicited, correlating with preexisting antibody titers. Clonal lineage analysis identified BA.5-skewed B mem cells that had redirected their specificity from the ancestral strain to BA.5 through somatic hypermutations. Moreover, B mem cells with redirected BA.5 specificity exhibited accelerated development compared with de novo B mem cells derived from naïve repertoires. This redirected BA.5 specificity demonstrated greater resilience to viral point mutation and adaptation to recent Omicron variants HK.3 and JN.1, months after the second BA.5 exposure, suggesting that existing B mem cells elicited by older vaccines can redirect their specificity toward newly evolving variants.

28 July 2022 in Viruses
Verified
Journal Article
Open access
PDF file
MSMasayuki Shimojima
Masayuki Shimojima
SSSatoko Sugimoto
Satoko Sugimoto
KUKunihiko Umekita
Kunihiko Umekita
TOTaishi Onodera
Taishi Onodera
KSKaori Sano
Kaori Sano
MSMasayuki Saijo
Masayuki Saijo
Severe fever with thrombocytopenia syndrome (SFTS) is an infectious disease with a high case fatality rate caused by the SFTS virus, and currently there are no approved specific treatments. Neutralizing monoclonal antibodies (mAbs) against the virus could be a therapeutic agent in SFTS treatment, but their development has not sufficiently been carried out. In the present study, mouse and human mAbs exposed to the viral envelope proteins Gn and Gc (16 clones each) were characterized in vitro and in vivo by using recombinant proteins, cell culture with viruses, and an SFTS animal model with IFNAR-/- mice. Neutralization activities against the recombinant vesicular stomatitis virus bearing SFTS virus Gn/Gc as envelope proteins were observed with three anti-Gn and six anti-Gc mAbs. Therapeutic activities were observed among anti-Gn, but not anti-Gc mAbs with neutralizing activities. These results propose an effective strategy to obtain promising therapeutic mAb candidates for SFTS treatment, and a necessity to reveal precise roles of the SFTS virus Gn/Gc proteins.

29 February 2024 in iScience
Verified
Journal Article
Open access
TITetsuya Inoue
Tetsuya Inoue
YYYuichiro Yamamoto
Yuichiro Yamamoto
KSKaoru Sato
Kaoru Sato
YOYuko Okemoto-Nakamura
Yuko Okemoto-Nakamura
YSYoshimi Shimizu
Yoshimi Shimizu
KNKohji Noguchi
Kohji Noguchi
A current challenge is the emergence of SARS-CoV-2 variants, such as BQ.1.1 and XBB.1.5, that can evade immune defenses, thereby limiting antibody drug effectiveness. Emergency-use antibody drugs, including the widely effective bebtelovimab, are losing their benefits. One potential approach to address this issue are bispecific antibodies which combine the targeting abilities of two antibodies with distinct epitopes. We engineered neutralizing bispecific antibodies in the IgG-scFv format from two initially non-neutralizing antibodies, CvMab-6 (which binds to the receptor-binding domain [RBD]) and CvMab-62 (targeting a spike protein S2 subunit epitope adjacent to the known anti-S2 antibody epitope). Furthermore, we created a bispecific antibody by incorporating the scFv of bebtelovimab with our anti-S2 antibody, demonstrating significant restoration of effectiveness against bebtelovimab-resistant BQ.1.1 variants. This study highlights the potential of neutralizing bispecific antibodies, which combine existing less effective anti-RBD antibodies with anti-S2 antibodies, to revive the effectiveness of antibody therapeutics compromised by immune-evading variants.